Biotech investing is high-risk, high-reward — many biotech companies operate at a loss and have no revenue, with valuations based on the potential of their drug rather than profit.
The journey from drug discovery to commercialisation spans 10-12 years and involves numerous challenges, including complex regulatory hurdles, significant funding needs, and high failure rates. Fewer than 10% of drug candidates make it to market.
But for those that do succeed, the financial rewards can be significant, with a successful drug potentially generating billions in revenue.
Understanding this complex journey is essential for investors who want to navigate the sector intelligently.
The stages of biotech development
Biotech companies progress through several key stages on their path to commercialisation. As they advance, the risk for investors decreases, but the investment case changes significantly at each stage.
- Discovery phase: At this stage, companies identify promising drug candidates, often in collaboration with academic partners. The science is speculative, and value is primarily tied to intellectual property (IP). Companies raise capital to move forward, with no guarantees of success at this early stage.
- Preclinical trials: Once a drug candidate is selected, it moves into animal testing to assess safety and efficacy. Positive preclinical results provide early confidence, but the drug is still a long way from human trials. Funding from private investors or grants supports further development.
- Clinical trials: These trials are divided into Phase I (safety), Phase II (efficacy), and Phase III (validation). As each phase progresses, the risk for investors decreases, particularly as the drug shows more promise in human trials. A successful Phase III trial can lead to major valuation increases.
- Commercialisation: After completing Phase III trials, the drug moves toward commercialisation, often through a partnership with a larger pharmaceutical company. This phase focuses on scaling the product, generating revenue, and securing regulatory approval for market launch.
Examples of biotech development stages
Recent initiatives from Australian biotech companies illustrate what the various stages of drug development look like. For example, Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) is still in the discovery and preclinical stages with its promising antibody aimed at enhancing radiotherapy for head and neck cancer.
Race Oncology Ltd (ASX:RAC, OTC:RAONF), meanwhile, is progressing through clinical trials, having recently treated its first patient with RC220, a cancer drug currently in Phase I.
Read more: Race Oncology treats first patient with RC220 in a milestone quarter
And Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is advancing through later clinical phases, aiming to reach the $1.8 billion oncology market with its PTX-100 drug.
Read more: Prescient Therapeutics eyes 'inflection point', US$1.8 billion market with cancer drug
As these companies move closer to commercialisation, investors will see different risk-reward dynamics depending on the stage of development.
Investment strategies: How to approach biotech stocks
Biotech investing requires a strategic approach tailored to each development stage. In the early stages, including discovery and preclinical trials, the risk is high, and investments should focus on the scientific strength and intellectual property of the drug.
As the drug progresses into Phase I and II trials, risk decreases, with positive Phase II results often leading to significant valuation increases. At this stage, investors should focus on clinical trial data and the drug’s potential for efficacy and safety in humans.
Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) is a company that has recently begun recruiting patients for a world-first trial targeting binge eating disorder, representing an example of an investment at the clinical trial stage.
By Phase III, as the drug nears market approval, the risk is further reduced, but potential returns may be smaller. Late-stage companies often attract acquisition interest or form partnerships with larger pharmaceutical firms.
These deals offer investors an exit opportunity, with potential returns through strategic partnerships or acquisitions as the drug nears commercialisation. For instance, Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has made strides in commercialisation with its FebriDx diagnostic test, recently securing a $3.17 million distribution deal in the US.
Read more: Lumos Diagnostics secures US$317 million US distribution milestone for FebriDx®
Considerations for biotech investors
Investing in biotech requires thorough research and an understanding of the sector’s unique dynamics. Consider the following:
- Regulatory environment: Monitoring the approval process and regulatory news is vital, as regulatory bodies like the US Food and Drug Administration or the Australian Therapeutic Goods Administration play a major role in the drug’s journey.
- Management team: Strong leadership is crucial in navigating the complexities of drug development. A proven track record in biotech adds confidence to the investment.
- Funding: Biotech companies require substantial capital, often relying on external sources like venture capital, grants or public markets. Investors should assess the company’s financial stability and ability to meet future capital needs.
Preparing for a long-term commitment
Biotech investing is not for short-term thinkers; it requires patience and a long-term perspective. Success hinges on identifying the right companies at key inflection points — whether they be during early-stage breakthroughs or positive Phase II results.
While the risks are substantial, the rewards for investors who remain disciplined and well-informed can be significant. By focusing on companies with solid funding, validated science, and experienced leadership, investors can better navigate the complexities of the biotech landscape and maximise their chances of long-term success.